Longaevus Technologies Ltd. has announced the spin-off of Elastin Biosciences following breakthrough preclinical results of three of its assets. Elastin Biosciences has successfully conducted experiments and identified three novel drug combinations that inhibit elastin degradation and foster its deposition, leading to an increase in elastin expression by 5-fold, and improving aortic elasticity in aged mice in vivo.
Boston Immune Technologies and Therapeutics Inc. (BITT) has been awarded funding by the National Institutes of Health (NIH) to support the preclinical development of BITT-101, its CD40 antagonist antibody for treating Sjögren’s syndrome. The award will help support steps toward an IND filing next year.
Researchers from University of Michigan presented preclinical data for the novel oxylipin analogue CS-585 being developed as an antithrombotic agent. CS-585 was synthesized as an orally available analogue of 12(S)-hydroxy-eicosatrienoic (12-HETrE), with potent and selective prostacyclin (IP) receptor agonist activity and ability.
A Spanish study led by scientists from the Cajal Institute and the National Center of Oncological Research (CNIO) combined the power of artificial neural networks and biological neuronal circuits to identify abnormal brain activity produced by secondary metastases in the CNS and classify these tumors. The work, published online on Aug. 30, 2023, in Cancer Cell, showed how damage in the brain did not depend on the tumor size but on the effect it produced on neuronal circuits, interrupting cell communication.
Purdue Research Foundation has prepared and tested new peptides acting as N-terminal Xaa-Pro-Lys N-methyltransferase 1 (NTMT1) inhibitors reported to be useful for the treatment of cancer.
F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented imidazole macrocycles acting as stimulator of interferon genes protein (STING; TMEM173) antagonists. They are reported to be useful for the treatment of cancer, autoimmune diseases, inflammatory, neurological, metabolic, cardiovascular and ocular disorders.
Research at Aurigene Oncology Ltd. has led to the identification of fused bicyclic heterocyclyl compounds acting as ubiquitin carboxyl-terminal hydrolase 1 (USP1) inhibitors and reported to be useful for the treatment of cancer.
A DE Shaw Research LLC patent reports N3-substituted uracil compounds acting as transient receptor potential cation channel subfamily A member 1 (TRPA1) antagonists. As such, they are reported to be useful for the treatment of pain, fibrosis, autoimmune disease, neurological, dermatological, cardiovascular, respiratory and gastrointestinal disorders, among others.
Wistar Institute of Anatomy & Biology has synthesized new 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors for the treatment of SARS-CoV-2 infection (COVID-19).
RSS
